Condition Center

Caps are associated with reduction in insulin costs, mainly driven by patients enrolled in health savings accounts Insulin out-of-pocket (OOP) cost caps are associated with a reduction in insulin OOP costs, but no increase in insulin use, according to a study published online March 26 in the Annals of Internal Medicine. Laura F. Garabedian, Ph.D., M.P.H.,...

An analysis of data from the International Multiple Sclerosis Genetics Consortium identified five proteins that could be targets of future drug therapies for managing progressive multiple sclerosis. Multiple sclerosis (MS) is a prevalent chronic neurological disease affecting young adults, characterized by inflammatory attacks followed by progressive disability. While current therapies primarily target inflammation and relapsing...

COVID-19 may alter NMOSD and MS risk and appears to be related to genetic susceptibility, a systemic review indicates. Multiple sclerosis (MS) is a common central nervous system (CNS) condition with axonal damage, and its pathogenesis is unclear, though much is known about its risk factors. On the other hand, neuromyelitis optica spectrum disorder (NMOSD) is...

In a phase III study, the administration of pembrolizumab with chemotherapy provided progression-free survival and overall survival benefits with a satisfactory safety profile compared to placebo in previously untreated patients with metastatic squamous non-small-cell lung cancer. The KEYNOTE-407 phase III study assessed the long-term survival outcomes in metastatic squamous non-small-cell lung cancer (NSCLC) patients treated...

Trastuzumab deruxtecan demonstrated an acceptable safety profile and was associated with a clinically significant objective response rate in patients with HER2-mutant metastatic non-small-cell lung cancer in a phase II study. Human epidermal growth factor receptor (HER2) mutations are present in a small number of non-squamous non-small-cell lung cancer (NSCLC) patients. Trastuzumab deruxtecan (T-DXd) is approved...

Second study shows low rate of SGLT2i prescribing even among patients with indications for therapy Pharmacy dispensing patterns for sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP1-RA) medications show lower prescribing for minority patients; and the rate of SGLT2i prescriptions is low among patients with indications for therapy, according to two...

Viral load rebound, symptom rebound common with VV116, nirmatrelvir-ritonavir in mild-to-moderate COVID-19 For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or nirmatrelvir-ritonavir, according to a study published online March 13 in JAMA Network Open. Zhitao Yang, M.D., from Ruijin Hospital in Shanghai,...

Significantly lower rates seen for all-cause mortality and unnatural-cause mortality, but not natural-cause mortality For individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD), medication initiation is associated with a significantly lower rate of all-cause mortality and unnatural-cause mortality, according to a study published in the March 12 issue of the Journal of the American Medical Association. Lan Li,...

In the IDEA trial, postmenopausal patients aged 50–69 years with pT1N0 unifocal invasive breast cancer who did not receive radiotherapy achieved a high level of disease control after 5 years. For over three decades, radiotherapy has been an essential part of the treatment following breast-conserving surgery (BCS) for patients with early-stage breast cancer. Recent studies...